|
Pfizer and BioNTech celebrate historic first authorization in the U.S. of vaccine to prevent COVID-19
|
14 December 2020 |
|
Pfizer and BioNTech receive FDA Advisory Committee vote supporting potential first Emergency Use Authorization for vaccine to combat COVID-19 in the U.S.
|
11 December 2020 |
|
Pfizer and BioNTech announce publication of results from landmark Phase 3 trial of BNT162b2 COVID-19 vaccine candidate in The New England Journal of Medicine
|
10 December 2020 |
|
Pfizer and BioNTech achieve Health Canada authorization for their vaccine to combat COVID-19
|
09 December 2020 |
|
Pfizer and BioNTech achieve first authorization in the world for a vaccine to combat COVID-19
|
02 December 2020 |
|
Pfizer and BioNTech to submit Emergency Use Authorization request today to the U.S. FDA for COVID-19 vaccine
|
20 November 2020 |
|
Pfizer and BioNTech conclude Phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints
|
18 November 2020 |
|
Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from Phase 3 study
|
09 November 2020 |
|
BioNTech and Pfizer initiate rolling submission to European Medicines Agency for SARS-CoV-2 vaccine candidate BNT162b2
|
06 October 2020 |
|
Pfizer and BioNTech propose expansion of pivotal COVID-19 vaccine trial
|
14 September 2020 |
|
Pfizer and BioNTech announce data from preclinical studies of mRNA-based vaccine candidate against COVID-19
|
09 September 2020 |
|
Pfizer and BioNTech share positive early data on lead mRNA vaccine candidate BNT162b2 against COVID-19
|
21 August 2020 |
|
Pfizer announces agreement with Gilead to manufacture remdesivir for treatment of COVID-19
|
11 August 2020 |
|
Pfizer and BioNTech to supply Japan with 120 million doses of their BNT162 mRNA-based vaccine candidate
|
31 July 2020 |
|
Pfizer and BioNTech choose lead mRNA vaccine candidate against COVID-19 and commence pivotal Phase 2/3 global study
|
28 July 2020 |
|
Pfizer and BioNTech announce an agreement with U.S. Government for up to 600 million doses of mRNA-based vaccine aandidate against SARS-CoV-2
|
27 July 2020 |
|
Pfizer and BioNTech announce agreement with the United Kingdom for 30 million doses of mRNA-based vaccine candidate against SARS-CoV-2
|
27 July 2020 |
|
Pfizer and BioNTech granted FDA Fast Track designation for two investigational mRNA-based vaccine candidates against SARS-CoV-2
|
14 July 2020 |
|
Pfizer and BioNTech announce early positive data from an ongoing Phase 1/2 study of mRNA-based vaccine candidate against SARS-CoV-2
|
01 July 2020 |
|
Pfizer and BioNTech dose first participants in the U.S. as part of global COVID-19 mRNA vaccine development program
|
11 May 2020 |